- Home
- ANET vs GILD Comparison
ANET vs GILD Comparison
Compare ANET & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANET | GILD |
|---|---|---|
| Founded | 2004 | 1987 |
| Country | United States | United States |
| Employees | 4412 | N/A |
| Industry | Computer Communications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.1B | 147.6B |
| IPO Year | 2014 | 1992 |
Fundamental Metrics
Financial Performance| Metric | ANET | GILD |
|---|---|---|
| Price | $132.40 | $124.78 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 20 |
| Target Price | ★ $163.00 | $127.60 |
| AVG Volume (30 Days) | 7.3M | ★ 7.8M |
| Earning Date | 11-04-2025 | 02-10-2026 |
| Dividend Yield | N/A | ★ 2.54% |
| EPS Growth | 26.15 | ★ 6514.05 |
| EPS | 2.63 | ★ 6.42 |
| Revenue | $8,448,346,000.00 | ★ $29,087,000,000.00 |
| Revenue This Year | $29.41 | $3.63 |
| Revenue Next Year | $21.54 | $2.97 |
| P/E Ratio | $49.86 | ★ $19.35 |
| Revenue Growth | ★ 27.75 | 2.79 |
| 52 Week Low | $59.43 | $88.57 |
| 52 Week High | $164.94 | $128.70 |
Technical Indicators
Market Signals| Indicator | ANET | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 52.92 | 56.71 |
| Support Level | $121.63 | $118.17 |
| Resistance Level | $127.84 | $123.74 |
| Average True Range (ATR) | 5.00 | 2.85 |
| MACD | 0.64 | -0.08 |
| Stochastic Oscillator | 71.80 | 86.30 |
Price Performance
Historical ComparisonAbout ANET Arista Networks Inc.
Arista Networks is a networking equipment provider that primarily sells Ethernet switches and software to data centers. Its marquee product is its extensible operating system, or EOS, that runs a single image across every single one of its devices. The firm operates as one reportable segment. It has steadily gained market share since its founding in 2004, with a focus on high-speed applications. Arista counts Microsoft and Meta Platforms as its largest customers and derives roughly three quarters of its sales from North America.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).